Related Experiment Video
Updated: Aug 1, 2026

Expression, Detergent Solubilization, and Purification of a Membrane Transporter, the MexB Multidrug Resistance Protein
Published on: December 3, 2010
Multidrug resistance-associated protein: a protein distinct from P-glycoprotein involved in cytotoxic drug expulsion
M A Barrand1, T Bagrij, S Y Neo
1Department of Pharmacology, University of Cambridge.
Abstract:
1. Multidrug resistance (MDR) is a phenomenon originally seen in cultured tumor cells that, following selection for resistance to a single anticancer agent, become resistant to a range of chemically diverse anticancer agents. These MDR cells show a decrease in intracellular drug accumulation due to active efflux by transporter proteins. The transporter best characterized is P-glycoprotein (Pgp). This protein has been identified in many cancers and has been the target for agents able to inhibit its action, thereby reversing resistance. 2. More recently, another transporter, multidrug resistance-associated protein (MRP) has been identified in a number of MDR human tumor cell lines that do not apparently express Pgp. The presence of MRP at the cell surface of these cells is associated with alterations in drug accumulation and distribution. 3. The gene-encoding MRP has been cloned and sequenced and shown by transfection studies to be able to confer resistance and changes in drug accumulation in sensitive tumor cells. The profile of anticancer drugs expelled in the presence of MRP is similar, but not identical, to that of Pgp. 4. MRP has been identified in a number of different types of cancers, but it is not yet clear to what extent it is involved with clinical resistance. Furthermore, resistance modulators useful against Pgp are less effective in reversing MRP-mediated resistance. 5. It is not fully understood how MRP brings about drug efflux, but it is clear that the underlying mechanisms are different from those responsible for Pgp-mediated drug efflux. In particular, glutathione (GSH) is required for the effective expulsion of the anticancer agents. 6. Unlike Pgp, MRP is able to transport metallic oxyanions and glutathione and other conjugates, including peptidyl leukotrienes. Agents that inhibit organic anion transport, such as probenecid, can block MRP activity. 7. Like Pgp, MRP is expressed not only in resistant tumor cells, but also in normal human tissues. These include the epithelial cells lining the airways and the gastrointestinal tract. In cells in normal tissues, MRP appears to be located within the cytoplasm, which may mean that it functions here in a manner slightly different to that in malignant cells. It is now also recognized in cells and tissues from other species, such as the rat and mouse.
Insights
Multidrug resistance (MDR) involves transporter proteins like P-glycoprotein (Pgp) and multidrug resistance-associated protein (MRP). MRP, distinct from Pgp, expels anticancer drugs and requires glutathione for its function.
Area of Science:
- Biochemistry
- Molecular Biology
- Cancer Research
Background:
- Multidrug resistance (MDR) in cancer cells arises from decreased drug accumulation due to efflux transporters.
- P-glycoprotein (Pgp) is a well-characterized MDR transporter.
- Multidrug resistance-associated protein (MRP) is another identified transporter in MDR cells, distinct from Pgp.
Purpose of the Study:
- To investigate the role and mechanisms of MRP in multidrug resistance.
- To compare MRP-mediated drug resistance with Pgp-mediated resistance.
- To explore potential resistance modulators for MRP.
Main Methods:
- Cloning and sequencing of the MRP gene.
- Transfection studies to assess MRP's ability to confer resistance.
- Characterization of drug efflux profiles and dependence on glutathione (GSH).
- Identification of MRP in various human cancers and normal tissues.
Main Results:
- The MRP gene confers resistance and alters drug accumulation in sensitive cells.
- MRP-mediated drug efflux differs from Pgp, requiring GSH for anticancer agent expulsion.
- MRP transports metallic oxyanions, GSH conjugates, and peptidyl leukotrienes.
- Probenecid inhibits MRP activity by blocking organic anion transport.
- MRP is found in both resistant tumor cells and normal tissues, with differing cellular localization.
Conclusions:
- MRP represents a distinct mechanism of multidrug resistance compared to Pgp.
- Understanding MRP's unique efflux mechanisms and substrate specificities is crucial for developing novel cancer therapies.
- Further research is needed to clarify MRP's clinical significance in cancer resistance and to identify effective resistance modulators.
More Related Videos
09:44Small-Scale Plasma Membrane Preparation for the Analysis of Candida albicans Cdr1-mGFPHis
Published on: June 13, 2021
05:06Characterizing Multidrug Efflux Systems in Acinetobacter baumannii Using an Efflux-Deficient Bacterial Strain and a Single-Copy Gene Expression System
Published on: January 5, 2024
Related Concept Videos
ABC Transporters: Exporter
Treatment Resistant Cancers
Export of Misfolded Proteins out of the ER
Carrier-Mediated Transport
Active transport involves two types of membrane-spanning transporters: uptake and efflux. Uptake transporters are expressed in the small...
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
Mechanism of Antibiotic Resistance in MRSA